Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Basket Study of FS118 in Advanced and Early-Stage Malignancies
2021-003406-47Phase 2Completed
- Sponsor
- F-star
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FS118 in non-small cell lung cancer (NSCLC) and cancer, sponsored by F-star. Primary endpoint: Radiological response (Cohort A). Started Jan 2022; status: completed.
02
Drugs
FS118
03
Conditions
non-small cell lung cancer (NSCLC)cancer
Beyond the preview
Go deeper on 2021-003406-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003406-47.